Emergence Therapeutics licences Synaffix platformSynaffix B.V. and Emergence Therapeutics AG have entered into a licensing agreement of up to $360m to find ADCs directed against target molecules from Emergence. more ➔
Abivax SA Abivax SA bags €49.2m to push ABX-464Paris-based Abivax SA has cashed in €49.2m in an oversubscribed financing with top-tier US and European biotech investors. more ➔
BioEcho Life Sciences launches US subsidiaryGerman nucleic acid extraction specialist BioEcho Life Sciences has opened a subsidiary in Boston to supply the huge US-american market. more ➔ more ➔
Belgian researchers create extraembryonic mesoderm cellsResearchers from KU Leuven for the first time have produced human cells able to mimic the molecular mechanisms of early human embryogenesis and related defects. more ➔
SARS-CoV-2 infection triggers chronic fatigue syndromeA small prospective study among mid-aged people has demonstrated that a mild SARS-CoV-2 infection triggers ME/CF in 50% of the study population.<button lang="en-GB" aria-description="Klicken, … more ➔
Danish Bactolife A/S grabs fundingSwedish food and feed supplement specialist Bactolife A/S has received US$5m in funding from the Bill & Melinda Gates Foundation to address gastrointestinal infections. more ➔
Moderna launches patent dispute with BioNTech/PfizerFor the second time within a short period of time, a competitor has sued the mRNA vaccine developer BioNtechPfizer for patent infringement. more ➔
Belgian eTheRNA raises €39m in Series B2 financingModerna co-founder Kenneth Chien and Novalis LifeSciences LLC are the lead investors of a €39m Series B2 financing in eTheRNA. more ➔
Kinarus announces CHF 20 million convertible bond issueKinarus Therapeutics Holding AG has raised US$20m in financing through the issuance of convertible bonds to YA II PN, Ltd. more ➔
Cancer: Western life style is a killerA study in the scientific journal The Lancet shows that half of all global cancer deaths are due to life style-related risk factors such as smoking and alcohol use. more ➔
Abivax SA
